About US
Contact us
-
Merck, Bayer's trial win for heart failure rival could actually boost Novartis' EntrestoNovartis' Entresto, the clear-cut market leader in heart failure,has been soul-searching since its highly touted trial in an untreated population fell flat. Now, a surprise competitor has cropped up—2019/11/13
-
Inside Purdue Pharma's media playbook: How it planted the opioid 'anti-story'This story is a collaboration betweenProPublicaandStat. In 2004, Purdue Pharma was facing a threat to sales of its blockbuster opioid painkiller OxyContin, which were approaching $2 billion a year. W2019/11/12
-
AZ, Merck and Novartis top Big Pharma's Q3 growth charts. Teva and Pfizer? Not so muchThe drug industryfaces no shortage of challenges, from pricing threats and payer clampdowns to stepped-up competition and supply shortages. But a look atthird-quarter numbersshows many top playersare2019/11/12
-
Sorry, Shkreli: Supreme Court rebuffs ex-pharma CEO's final appealMartin Shkreli, the disgraced former CEO of Retrophin currently serving a seven-year sentence for securities fraud and conspiracy, was hoping for a SCOTUS Hail Mary after multiple appeals fell flat.2019/11/11
-
Hit by copycat meds, Amgen trims 172 more jobs, this time in operations, R&D and salesAmgen's top linehassuffered from knockoff competition in recent quarters, and now the painis moving to its payroll. After disclosing almost 150 cuts on the East Coast last week, the biotech giant now2019/11/11
-
Pfizer scores FDA nod for biosim to AbbVie's Humira, but it'll have to wait till 2023 to launchAbbVie is preparing for the costly U.S. loss of Humira exclusivity in 2023, and now there’s another pharma giant that has scored a biosimilar nod. Pfizer’sAbrilada, abiosimto AbbVie’smegablockbusterH2019/11/8
-
Bristol-Myers’ $74B Celgene buy wins antitrust nod in FTC party-line split voteIndustry watchers largely expected that Bristol-Myers Squibb and Celgene would win U.S. antitrust clearance for their $74 billion merger. But what’s perhaps unexpected is that the permission was not2019/11/8
-
Oklahoma judge chops $107M from Johnson & Johnson's opioid verdictAfter losing thenation’s first major opioid trial in Oklahoma this summer,Johnson & Johnson lawyers sought to reduce the company'sliability. Now, a judge has chopped more than $100 million off th2019/11/7
-
AHA: Amarin's Vascepa halts progression of arterial plaque in key studyPHILADELPHIA—One year after a cardiovascular outcomes study for Amarin's Vascepa took the American Heart Association's (AHA's) Scientific Sessions by storm, the fish-oil derivativeis back—and on the2019/11/7
-
AbbVie may count on Allergan's Botox for post-merger growth. But what else?With a $63 billion merger nearing approval, AbbVie is counting onAllergan and its cash-cow Botox to boost sales—and that superstar could be a long-term winner. But not every drug in Allergan's stable2019/11/6